Circulogene Microsatellite Instability Biomarker Testing

Circulogene announced the availability of microsatellite instability biomarker testing for multiple cancer types. The test is immediately available to oncologists and pathologists, enabling them to identify patients eligible for treatment with Keytruda (pembrolizumab) across multiple cancer types, or Opdivo (nivolumab) for colorectal cancer. With the new assay, Circulogene now provides circulating DNA, RNA, and MSI cancer immunotherapy testing from a single tube of blood with a three-day turnaround time out of it CLIA-certified laboratory.